Pavan Anne

ZS Impact Live 2026 - Boston Recap

ZS’s Arun Shastri at Healthcare Leadership Council briefing

ZS at PMSA 2026

Salesforce Life Sciences Innovation Day

Join our experts for a real-world look at how companies are blending the human with the digital to create AI strategies that take flight: bit.ly/47PBWZs

Why your best science is losing and what wins in pharma launches | ZS

On May 5, Impact Live Boston will welcome NASA Astronaut Sunita "Suni" Williams (Ret.) for a fireside chat. Suni brings a rare, practical perspective on preparedness, teamwork, risk and calm decision-making when it matters most. bit.ly/4tsLG45

Impact Live is landing in Boston May 5. See how future-focused AI-enabled decisioning comes from smarter market insights and patient-centric models. Register here: bit.ly/4bB9aOB #ZSImpactLive #HealthcareInnovation #BusinessTransformation

Forbes has recognized ZS among America’s Best Management Consulting Firms, for the 11th year in a row. Here’s to more than a decade of improving life and how we live it. bit.ly/4v8IbBJ

ZS Principal Adam D’Luzansky talks with Dalia Rayes, an experienced life sciences commercial executive, about how she helps biotechs translate scientific excellence into real patient impact. bit.ly/4aUb8rS

Reimagining clinical trials with In Silico and AI-driven methods

ZS has been recognized in Built In’s Best Places to Work awards. This year, we were named across multiple locations in the U.S., including in both the Best Places to Work Overall and Best Large Companies categories. #LifeAtZS #BPTW2026 bit.ly/49Jy6mb

ZS and Healthcare Leadership Council: New report

Direct to patient (DTP): Making innovative therapies accessible for everyone

ZS celebrates 1K+ promotions across the firm! It’s amazing to work alongside people who constantly raise the bar and support one another. Congrats to everyone who grew this year, and Happy New Year to the entire ZS community! 🎆 bit.ly/4qxMROq

This season, we’re thankful for the people and partnerships that help us improve life and how we live it. From all of us at ZS, we wish you joy this holiday season and in the year ahead. bit.ly/491fWKR

ASH 2025 signaled a shift in frontline CLL. New data from BRUIN CLL-313 and CLL17 move the debate beyond sequencing toward patient choice, durability and quality of life. Read more: bit.ly/4qeaFGL

CAR T and bispecifics are reshaping the MM “board.” ASH 2025 shows that sequencing now hinges on potential cure vs dependable management. See why evidence that preserves options will matter most. bit.ly/4s58hEg

As blockbuster ICIs shift from IV to sub-Q, what drives commercial success? Our latest analysis reveals 5 key factors shaping uptake and growth. bit.ly/4oQlxdc

ZS's innovative digital solution for rare disease diagnosis has been recognized as a finalist in the Fierce Life Sciences Innovation Awards. #DigitalHealth #FierceInnovation #RareDiseaseCare bit.ly/47uxgHm